vs
ImmunityBio, Inc.（IBRX）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
ImmunityBio, Inc.的季度营收约是RBB Bancorp的1.2倍（$38.3M vs $32.3M），RBB Bancorp净利率更高（31.5% vs -161.8%，领先193.3%），ImmunityBio, Inc.同比增速更快（407.0% vs 12.6%），RBB Bancorp自由现金流更多（$42.6M vs $-71.3M）
ImmunityBio, Inc.是一家处于临床阶段的生物技术企业，专注开发针对多种癌症及传染性疾病的下一代免疫疗法与候选疫苗，核心研发方向涵盖细胞疗法、抗体药物及靶向疫苗平台，主要运营市场位于美国。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
IBRX vs RBB — 直观对比
营收规模更大
IBRX
是对方的1.2倍
$32.3M
营收增速更快
IBRX
高出394.4%
12.6%
净利率更高
RBB
高出193.3%
-161.8%
自由现金流更多
RBB
多$113.9M
$-71.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $32.3M |
| 净利润 | $-61.9M | $10.2M |
| 毛利率 | 99.0% | — |
| 营业利润率 | -169.0% | 39.5% |
| 净利率 | -161.8% | 31.5% |
| 营收同比 | 407.0% | 12.6% |
| 净利润同比 | -4.7% | 132.1% |
| 每股收益（稀释后） | $-0.06 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBRXRBB
| Q4 25 | $38.3M | $32.3M | ||
| Q3 25 | $32.1M | $32.6M | ||
| Q2 25 | $26.4M | $35.8M | ||
| Q1 25 | $16.5M | $28.5M | ||
| Q4 24 | $7.6M | $28.7M | ||
| Q3 24 | $6.1M | $30.3M | ||
| Q2 24 | — | $27.5M | ||
| Q1 24 | — | $28.2M |
净利润IBRXRBB
| Q4 25 | $-61.9M | $10.2M | ||
| Q3 25 | $-67.3M | $10.1M | ||
| Q2 25 | $-92.6M | $9.3M | ||
| Q1 25 | $-129.6M | $2.3M | ||
| Q4 24 | $-59.2M | $4.4M | ||
| Q3 24 | $-85.7M | $7.0M | ||
| Q2 24 | — | $7.2M | ||
| Q1 24 | — | $8.0M |
毛利率IBRXRBB
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IBRXRBB
| Q4 25 | -169.0% | 39.5% | ||
| Q3 25 | -173.5% | 40.7% | ||
| Q2 25 | -269.8% | 36.1% | ||
| Q1 25 | -390.1% | 11.2% | ||
| Q4 24 | -919.0% | 17.6% | ||
| Q3 24 | -1314.3% | 31.6% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 39.9% |
净利率IBRXRBB
| Q4 25 | -161.8% | 31.5% | ||
| Q3 25 | -209.8% | 31.2% | ||
| Q2 25 | -350.3% | 26.1% | ||
| Q1 25 | -784.9% | 8.0% | ||
| Q4 24 | -783.4% | 15.3% | ||
| Q3 24 | -1404.0% | 23.1% | ||
| Q2 24 | — | 26.4% | ||
| Q1 24 | — | 28.4% |
每股收益（稀释后）IBRXRBB
| Q4 25 | $-0.06 | $0.59 | ||
| Q3 25 | $-0.07 | $0.59 | ||
| Q2 25 | $-0.10 | $0.52 | ||
| Q1 25 | $-0.15 | $0.13 | ||
| Q4 24 | $-0.08 | $0.26 | ||
| Q3 24 | $-0.14 | $0.39 | ||
| Q2 24 | — | $0.39 | ||
| Q1 24 | — | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $242.8M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $-500.5M | $523.4M |
| 总资产 | $501.9M | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资IBRXRBB
| Q4 25 | $242.8M | $212.3M | ||
| Q3 25 | $257.8M | $234.9M | ||
| Q2 25 | $153.7M | $191.9M | ||
| Q1 25 | $61.6M | $238.8M | ||
| Q4 24 | $149.8M | $257.7M | ||
| Q3 24 | $130.4M | $349.4M | ||
| Q2 24 | — | $252.8M | ||
| Q1 24 | — | — |
总债务IBRXRBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
股东权益IBRXRBB
| Q4 25 | $-500.5M | $523.4M | ||
| Q3 25 | $-524.3M | $514.3M | ||
| Q2 25 | $-570.7M | $517.7M | ||
| Q1 25 | $-591.4M | $510.3M | ||
| Q4 24 | $-489.1M | $507.9M | ||
| Q3 24 | $-745.1M | $509.7M | ||
| Q2 24 | — | $511.3M | ||
| Q1 24 | — | $514.0M |
总资产IBRXRBB
| Q4 25 | $501.9M | $4.2B | ||
| Q3 25 | $519.0M | $4.2B | ||
| Q2 25 | $402.1M | $4.1B | ||
| Q1 25 | $303.8M | $4.0B | ||
| Q4 24 | $382.9M | $4.0B | ||
| Q3 24 | $364.6M | $4.0B | ||
| Q2 24 | — | $3.9B | ||
| Q1 24 | — | $3.9B |
负债/权益比IBRXRBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.4M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $-71.3M | $42.6M |
| 自由现金流率自由现金流/营收 | -186.2% | 131.8% |
| 资本支出强度资本支出/营收 | 2.4% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | $-308.8M | $73.5M |
8季度趋势，按日历期对齐
经营现金流IBRXRBB
| Q4 25 | $-70.4M | $43.4M | ||
| Q3 25 | $-68.9M | $2.1M | ||
| Q2 25 | $-79.7M | $21.7M | ||
| Q1 25 | $-85.9M | $7.8M | ||
| Q4 24 | $-85.1M | $58.5M | ||
| Q3 24 | $-98.8M | $24.5M | ||
| Q2 24 | — | $11.7M | ||
| Q1 24 | — | $4.8M |
自由现金流IBRXRBB
| Q4 25 | $-71.3M | $42.6M | ||
| Q3 25 | $-69.6M | $1.8M | ||
| Q2 25 | $-80.8M | $21.6M | ||
| Q1 25 | $-87.0M | $7.6M | ||
| Q4 24 | $-87.3M | $57.7M | ||
| Q3 24 | $-101.6M | $24.2M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $4.7M |
自由现金流率IBRXRBB
| Q4 25 | -186.2% | 131.8% | ||
| Q3 25 | -217.2% | 5.4% | ||
| Q2 25 | -305.9% | 60.2% | ||
| Q1 25 | -526.9% | 26.7% | ||
| Q4 24 | -1155.4% | 201.0% | ||
| Q3 24 | -1663.2% | 80.0% | ||
| Q2 24 | — | 42.0% | ||
| Q1 24 | — | 16.6% |
资本支出强度IBRXRBB
| Q4 25 | 2.4% | 2.5% | ||
| Q3 25 | 2.3% | 1.1% | ||
| Q2 25 | 4.1% | 0.3% | ||
| Q1 25 | 6.8% | 0.6% | ||
| Q4 24 | 28.0% | 2.7% | ||
| Q3 24 | 45.7% | 0.8% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.5% |
现金转化率IBRXRBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
